Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.
Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 5, 7, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.
Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peanut Allergy - Overview
Peanut Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peanut Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peanut Allergy - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Aimmune Therapeutics Inc
Alfacyte Ltd
Allergy Therapeutics Plc
AnaptysBio Inc
ASIT Biotech SA
Astellas Pharma Inc
BioLingus AG
BlueWillow Biologics Inc
Cambridge Allergy Ltd
DBV Technologies SA
F. Hoffmann-La Roche Ltd
HAL Allergy BV
Inimmune Corp
Intrommune Therapeutics
Regeneron Pharmaceuticals Inc
Sanofi
Peanut Allergy - Drug Profiles
AK-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANN-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0892 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBV-712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etokimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HALMPE-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pnt-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polyvac Peanut - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVX-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-439794 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to target TLR for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTC-064 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peanut Allergy - Dormant Projects
Peanut Allergy - Discontinued Products
Peanut Allergy - Product Development Milestones
Featured News & Press Releases
Sep 12, 2018: DBV Technologies announces positive DSMB review of Part A of phase III study in peanut-allergic toddlers
Sep 06, 2018: Intrommune Therapeutics completes Pre-IND meeting with FDA on INT301 for peanut allergy
Aug 07, 2018: Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
Jul 26, 2018: DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Jun 11, 2018: Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
May 30, 2018: Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
May 29, 2018: DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018
May 28, 2018: Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress
May 16, 2018: DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors
May 15, 2018: Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
May 15, 2018: Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 08, 2018: DBV Technologies to Present New Clinical Data of Viaskin Peanut at the 2018 EAACI Meeting
Apr 24, 2018: Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peanut Allergy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H2 2018
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H2 2018
Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2018
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2018
Peanut Allergy - Pipeline by AnaptysBio Inc, H2 2018
Peanut Allergy - Pipeline by ASIT Biotech SA, H2 2018
Peanut Allergy - Pipeline by Astellas Pharma Inc, H2 2018
Peanut Allergy - Pipeline by BioLingus AG, H2 2018
Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H2 2018
Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H2 2018
Peanut Allergy - Pipeline by DBV Technologies SA, H2 2018
Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Peanut Allergy - Pipeline by HAL Allergy BV, H2 2018
Peanut Allergy - Pipeline by Inimmune Corp, H2 2018
Peanut Allergy - Pipeline by Intrommune Therapeutics, H2 2018
Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Peanut Allergy - Pipeline by Sanofi, H2 2018
Peanut Allergy - Dormant Projects, H2 2018
Peanut Allergy - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Peanut Allergy, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
